Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib

Darapladib, a lipoprotein-associated phospholipase A2 (Lp-PLA(2)) inhibitor, failed to demonstrate efficacy for the primary endpoints in two large phase III cardiovascular outcomes trials, one in stable coronary heart disease patients (STABILITY) and one in acute coronary syndrome (SOLID-TIMI 52). N...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:PLoS One
Κύριοι συγγραφείς: Yeo, Astrid, Li, Li, Warren, Liling, Aponte, Jennifer, Fraser, Dana, King, Karen, Johansson, Kelley, Barnes, Allison, MacPhee, Colin, Davies, Richard, Chissoe, Stephanie, Tarka, Elizabeth, O’Donoghue, Michelle L., White, Harvey D., Wallentin, Lars, Waterworth, Dawn
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Public Library of Science 2017
Θέματα:
Research Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5533343/
https://ncbi.nlm.nih.gov/pubmed/28753643
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0182115
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια